Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;24(1):15-28.
doi: 10.1615/critreveukaryotgeneexpr.2013006875.

Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases

Julio Morales  1 , Longshan Li  1 , Farjana J Fattah  1 , Ying Dong  1 , Erik A Bey  2 , Malina Patel  1 , Jinming Gao  1 , David A Boothman  1
Affiliations
Review

Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases

Julio Morales et al. Crit Rev Eukaryot Gene Expr. 2014.

Abstract

Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins. PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair. The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition. PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents. Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer. The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor. Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells. Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy. The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Dual therapeutic potential for PARP inhibition in oncology
FIG. 2
FIG. 2
PARP-mediated cell death mechanisms
FIG. 3
FIG. 3
Mechanisms of β-lapachone-induced toxicity in cancer cells
See this image and copyright information in PMC

References

    1. Amé J-C, Spenlehauer C, de Murcia G. The PARP super-family. BioEssays. 2004;26(8):882–93. - PubMed
    1. D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342(2):249–68. - PMC - PubMed
    1. Amé JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Höger T, Ménissier-de Murcia J, de Murcia G. PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase. J Biol Chem. 1999;274(25):17860–8. - PubMed
    1. Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S, Zia’ee AA. The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea. Eur J Biochem. 1979;101(1):135–42. - PubMed
    1. Juarez-Salinas H, Sims JL, Jacobson MK. Poly(ADP-ribose) levels in carcinogen-treated cells. Nature. 1979;282(5740):740–1. - PubMed